Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)Fecal Microbiota Transplantation
Investigational drug(s) / intervention(s)
Fecal microbiota transplantationinfliximab
Fecal microbiota transplantation: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
infliximab: Intravenous infusion of infliximab once every 8 weeks.
Study summary
This study enrolled 94 patients with UC or CD. Two groups received either 8-week intestinal bacterial transplant capsule therapy or biological therapy, respectively. The control group received biological therapy alone, while the experimental group received biological therapy combined with FMT. Both groups were followed up for 52 weeks after discharge. The efficacy of FMT capsule therapy on the subjects' UC or CD symptom-related scores and its effect on remodeling the intestinal flora were observed, and its safety was verified.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* The diagnosis was UC or CD, and the diagnosis was based on clinical, endoscopic and pathological evidence.
* IBD should be diagnosed for at least 6 months to rule out the possibility of natural remission of new cases.
* Patients should be in mild to moderate active stage (UC: Mayo score 3-10; CD: CDAI score: 150-449)
* Biological agents (such as anti-TNF-α drugs, vedolizumab, etc.) were used in the past, but no clinical remission was achieved.
* Voluntary participation and signing of informed consent.
* Adults aged 18-65.
* Can tolerate oral enterobacteria transplantation capsule treatment.
Exclusion Criteria:
* The diagnosis was UC or CD, and the diagnosis was based on clinical, endoscopic and pathological evidence.
* IBD should be diagnosed for at least 6 months to rule out the possibility of natural remission of new cases.
* Patients should be in mild to moderate active stage (UC: Mayo score 3-10; CD: CDAI score: 150-449)
* Biological agents (such as anti-TNF-α drugs, vedolizumab, etc.) were used in the past, but no clinical remission was achieved.
* Voluntary participation and signing of informed consent.
* Adults aged 18-65.
* Can tolerate oral enterobacteria transplantation capsule treatment.
Primary outcome measure(s)
Endoscopic remission rate — 14th and 52nd week after joining the group. UC is endoscopic Mayo score 0-1; CD is simple endoscopic score (SES-CD)\<3 or no ulcer.
Clinical remission rate — 14th and 52nd week after joining the group. UC is defined as Mayo score ≤2, and no single score \> 1; CD is defined as CDAI (Crohn's disease activity index) \< 150.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.